You are here

  • Home
  • Archive
  • Volume 75, Issue 5
  • Response to: ‘Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required’ by Moots et al

Article Text

Article menu

Download PDFPDF

Electronic pages
Correspondence response
Response to: ‘Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required’ by Moots et al
  1. Paul Emery1,2,
  2. Jiří Vencovský3,
  3. Jeehoon Ghil4
  1. 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
  2. 2NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK
  3. 3Institute of Rheumatology, Prague, Czech Republic
  4. 4Samsung Bioepis Co., Ltd., Incheon, Republic of Korea
  1. Correspondence to Professor Paul Emery, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK; p.emery{at}leeds.ac.uk

http://dx.doi.org/10.1136/annrheumdis-2016-209203

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Dr Moots and colleagues1 for the questions regarding the immunogenicity results in our study.2

    While it seems that there was much concern about the details of the methods and results of the immunogenicity data, the authors would like to reassure Dr Moots and colleagues that the presented data are valid and reliable and follow standard reporting procedures. We provide the following explanations and that they are helpful in this respect.

    The proportion of patients who tested positive for antidrug antibodies (ADAs) at least once up to Week 24 was significantly lower in SB4 compared with the etanercept reference product (ETN) (2 patients (0.7%) in SB4 and 39 patients (13.1%) in ETN, p<0.001). Only one in the ETN group had neutralising capacity.2 The incidence of patients with positive ADA by titre up to Week 24 is presented in table 1. Almost all ADAs were transient, which is consistent with the previous studies with ETN.3 ,4 All patients were reported as positive only once throughout the …

    View Full Text

    Linked Articles